Fate Therapeutics(FATE)
$1.61-0.17 (-9.32%)
FATE
Fate Therapeutics financials statements
$1.61
At close:-0.17 (-9.32%)
Want to see FATE full AI Analyst Report?
Fate Therapeutics (FATE) Ratios
1,295 Followers
Fate Therapeutics Ratios
FATE's free cash flow for Q3 2026 was $-27.89M. For the 2026 fiscal year, FATE's free cash flow was increased by $0.00 and operating cash flow was $-27.89M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 |
| Quick Ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 |
| Cash Ratio | 1.29 | 0.94 | 1.07 | 0.54 | 1.64 |
| Solvency Ratio | -1.14 | -1.37 | -1.04 | -1.21 | -0.85 |
| Operating Cash Flow Ratio | -2.94 | -3.19 | -3.38 | -2.18 | -2.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 96.95M | $ 169.94M | $ 193.74M | $ 280.45M | $ 390.80M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.24 | 0.19 | 0.20 | 0.15 | 0.12 |
| Debt-to-Equity Ratio | 0.38 | 0.27 | 0.28 | 0.23 | 0.17 |
| Debt-to-Capital Ratio | 0.27 | 0.21 | 0.22 | 0.18 | 0.14 |
| Long-Term Debt-to-Capital Ratio | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.54 | 1.38 | 1.37 | 1.46 | 1.36 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.63 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.66 | 0.75 | 1.05 | 1.13 | 1.21 |
| Net Debt to EBITDA | -0.25 | -0.28 | -0.36 | -0.16 | 0.09 |
| Profitability Margins | |||||
| Gross Profit Margin | -94.12% | -769.57% | -147.41% | 85.71% | 89.52% |
| EBIT Margin | -2051.08% | -1434.52% | -299.86% | -320.23% | -388.56% |
| EBITDA Margin | -1911.22% | -1295.41% | -271.09% | -305.95% | -378.08% |
| Operating Profit Margin | -2222.45% | -1542.63% | -299.86% | -320.23% | -388.56% |
| Pretax Profit Margin | -2051.08% | -1366.46% | -253.30% | -292.55% | -379.89% |
| Net Profit Margin | -2051.08% | -1366.46% | -253.30% | -292.55% | -379.89% |
| Continuous Operations Profit Margin | -2051.08% | -1366.46% | -253.30% | -292.55% | -379.89% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.29% | 88.58% | 84.47% | 91.35% | 97.77% |
| Return on Assets (ROA) | -42.74% | -42.27% | -31.79% | -39.93% | -23.02% |
| Return on Equity (ROE) | -65.79% | -58.44% | -43.68% | -58.21% | -31.25% |
| Return on Capital Employed (ROCE) | -52.22% | -52.29% | -40.78% | -52.14% | -25.83% |
| Return on Invested Capital (ROIC) | -51.39% | -51.34% | -40.25% | -51.64% | -25.66% |
| Return on Tangible Assets | -42.74% | -42.27% | -31.79% | -39.93% | -23.02% |
| Earnings Yield | -116.79% | -99.30% | -43.72% | -28.84% | -3.83% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.26 | 3.85 | 34.79 | 2.50 | 6.44 |
| Payables Turnover | 4.86 | 12.66 | 33.31 | 1.66 | 0.68 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.07 | 0.12 | 0.40 | 1.46 | 0.34 |
| Asset Turnover | 0.02 | 0.03 | 0.13 | 0.14 | 0.06 |
| Working Capital Turnover Ratio | 0.03 | 0.05 | 0.19 | 0.20 | 0.12 |
| Cash Conversion Cycle | -24.84 | 65.93 | -0.47 | -73.42 | -480.63 |
| Days of Sales Outstanding | 50.31 | 94.76 | 10.49 | 145.85 | 56.70 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 75.14 | 28.84 | 10.96 | 219.27 | 537.33 |
| Operating Cycle | 50.31 | 94.76 | 10.49 | 145.85 | 56.70 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.89 | -1.08 | -1.34 | -2.56 | -1.72 |
| Free Cash Flow Per Share | -0.94 | -1.09 | -1.41 | -2.93 | -2.25 |
| Dividend Paid and CapEx Coverage Ratio | -17.82 | -168.32 | -21.50 | -6.98 | -3.21 |
| Capital Expenditure Coverage Ratio | -17.82 | -168.32 | -21.50 | -6.98 | -3.21 |
| Operating Cash Flow Coverage Ratio | -1.36 | -1.44 | -1.28 | -2.27 | -1.42 |
| Operating Cash Flow to Sales Ratio | -15.96 | -9.01 | -2.08 | -2.58 | -2.92 |
| Free Cash Flow Yield | -95.99% | -65.89% | -37.61% | -29.05% | -3.85% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.85 | -1.01 | -2.29 | -3.47 | -26.13 |
| Price-to-Sales (P/S) Ratio | 17.56 | 13.76 | 5.79 | 10.15 | 99.27 |
| Price-to-Book (P/B) Ratio | 0.56 | 0.59 | 1.00 | 2.02 | 8.17 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.04 | -1.52 | -2.66 | -3.44 | -25.96 |
| Price-to-Operating Cash Flow Ratio | -1.10 | -1.53 | -2.78 | -3.94 | -34.04 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.00 | 0.05 | -0.12 | -3.92 |
| Enterprise Value Multiple | -1.16 | -1.34 | -2.50 | -3.48 | -26.17 |
| Enterprise Value | 147.94M | 236.79M | 429.72M | 1.02B | 5.52B |
| EV to EBITDA | -1.16 | -1.34 | -2.50 | -3.48 | -26.17 |
| EV to Sales | 22.26 | 17.37 | 6.76 | 10.64 | 98.93 |
| EV to Free Cash Flow | -1.32 | -1.92 | -3.10 | -3.61 | -25.87 |
| EV to Operating Cash Flow | -1.39 | -1.93 | -3.25 | -4.13 | -33.92 |
| Tangible Book Value Per Share | 1.74 | 2.80 | 3.74 | 5.00 | 7.16 |
| Shareholders’ Equity Per Share | 1.74 | 2.80 | 3.74 | 5.00 | 7.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.06 | 0.12 | 0.65 | 0.99 | 0.59 |
| Net Income Per Share | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.95 | 0.84 | 0.91 | 0.98 |
| Research & Development to Revenue | 16.22 | 9.90 | 2.72 | 3.33 | 3.86 |
| SG&A to Revenue | 7.00 | 6.65 | 1.28 | 0.87 | 1.03 |
| Stock-Based Compensation to Revenue | 3.75 | 3.04 | 0.68 | 0.82 | 0.97 |
| Income Quality | 0.78 | 0.66 | 0.82 | 0.88 | 0.77 |
Currency in USD
